Casey Woodring
Stock Analyst at JP Morgan
(1.00)
# 3,925
Out of 5,122 analysts
58
Total ratings
30.3%
Success rate
-10.63%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $85 → $80 | $61.47 | +30.14% | 1 | Dec 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $250 → $260 | $231.30 | +12.41% | 3 | Dec 15, 2025 | |
| ILMN Illumina | Maintains: Neutral | $105 → $130 | $134.48 | -3.33% | 2 | Dec 15, 2025 | |
| GH Guardant Health | Maintains: Overweight | $90 → $120 | $101.39 | +18.35% | 2 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $165 → $190 | $203.16 | -6.48% | 10 | Dec 15, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $55 | $48.44 | +13.54% | 1 | Dec 15, 2025 | |
| BLLN BillionToOne | Maintains: Overweight | $150 → $145 | $84.51 | +71.58% | 2 | Dec 10, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $180 | $137.93 | +30.50% | 2 | Nov 25, 2025 | |
| QDEL QuidelOrtho | Maintains: Underweight | $26 → $22 | $29.30 | -24.91% | 5 | Nov 7, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $15 | $16.15 | -7.12% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $17.76 | -9.91% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $11.38 | +5.45% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $255 | $227.11 | +12.28% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 | $74.51 | +4.69% | 6 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $325 | $385.10 | -15.61% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $585.07 | +11.10% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,419.47 | -9.47% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $182.36 | -17.75% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $56 | $45.60 | +21.97% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $2.43 | +146.91% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $21.23 | +8.36% | 2 | Oct 31, 2023 |
Tempus AI
Dec 15, 2025
Maintains: Neutral
Price Target: $85 → $80
Current: $61.47
Upside: +30.14%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $231.30
Upside: +12.41%
Illumina
Dec 15, 2025
Maintains: Neutral
Price Target: $105 → $130
Current: $134.48
Upside: -3.33%
Guardant Health
Dec 15, 2025
Maintains: Overweight
Price Target: $90 → $120
Current: $101.39
Upside: +18.35%
Charles River Laboratories International
Dec 15, 2025
Maintains: Neutral
Price Target: $165 → $190
Current: $203.16
Upside: -6.48%
Bruker
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $48.44
Upside: +13.54%
BillionToOne
Dec 10, 2025
Maintains: Overweight
Price Target: $150 → $145
Current: $84.51
Upside: +71.58%
Agilent Technologies
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $137.93
Upside: +30.50%
QuidelOrtho
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $29.30
Upside: -24.91%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $16.15
Upside: -7.12%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $17.76
Upside: -9.91%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $11.38
Upside: +5.45%
Oct 29, 2025
Maintains: Overweight
Price Target: $177 → $255
Current: $227.11
Upside: +12.28%
Oct 22, 2025
Downgrades: Neutral
Price Target: $78
Current: $74.51
Upside: +4.69%
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $385.10
Upside: -15.61%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $585.07
Upside: +11.10%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,419.47
Upside: -9.47%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $182.36
Upside: -17.75%
Jun 18, 2024
Maintains: Overweight
Price Target: $54 → $56
Current: $45.60
Upside: +21.97%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $2.43
Upside: +146.91%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $21.23
Upside: +8.36%